Defibrase^® is the trademark registered by Pentapharm for its Active Pharmaceutical Ingredient (API) Batroxobin, a serine protease.

Batroxobin is a thrombin-like enzyme purified from the snake venom of Bothrops moojeni.
Batroxobin is a pure single-chain glycopeptide with a molecular weight of approx. 32’600 Dalton.
In contrast to thrombin, which converts fibrinogen into fibrin by splitting off fibrinopeptides A and B, batroxobin only splits off fibrinopeptide A.
The enzyme has a defibrinogenating effect and is used clinically for the treatment of thrombotic diseases.

Pharmacological activity

• Decrease in fibrinogen levels, anticoagulation, inhibition of thrombogenesis
• Reduction of whole blood and plasma viscosity
• Improvement of hemorheology and microcirculation

Main therapeutic applications

• Acute cerebral infarction (registered only in China)
• Ischemia caused by vascular occlusive diseases (such as Thromboangiitis obliterans, deep vein thrombosis, and pulmonary embolism)
• Peripheral and microcirculation dysfunctions (such as sudden deafness, vibration disease)

API current registration status

• China
• Japan